• The hidden threat to big banks that may be worse than a housing collapse

    Scared woman

    The biggest single risk factor facing the big four ASX banks may not be as worrisome as another growing threat.

    While all eyes are on the large provisioning set aside by our largest mortgage lenders due to fears of consumer and SME loan defaults, its $63 billion of commercial property loans that’s keeping bankers awake at night.

    This is according to a report in the Australian Financial Review quoting unnamed senior banking executives.

    Dividend and earnings threat

    This could be a surprise to many as the attention is placed on over indebted households and small businesses most exposed to the devastating COVID-19 shutdown.

    This is why the National Australia Bank Ltd. (ASX: NAB) share price was under the most pressure during the coronavirus fallout as it is most exposed to small business lending.

    But Westpac Banking Group (ASX: WBC), Commonwealth Bank of Australia (ASX: CBA) and Australia and New Zealand Banking Group (ASX: ANZ) are also under pressure with the big four collectively setting aside more than $5 billion to due with problem loans.

    Loan provisions under threat

    Provisioning may have to increase if commercial property loans become as big a risk factor as the AFR is suggesting.

    That means the big dividend cuts we’ve seen over the past three months may be a more permanent feature than what many are forecasting.

    Bankers are worried because large companies and multinationals may decide they do not need large expensive offices in the CBD anymore.

    Structural risks to ASX banks

    The COVID-19 lockdown that forced record numbers of Australians to work from home is driving this rethinking. Aussies are equally if not more productive working from home. Law practices, accounting firms and investment banks may be tempted to economise by saving on rent.

    If this happens, landlords will be forced to write-down the value of their prime properties. This will be a problem for the big banks who are using these high-end addresses as loan collateral.

    While the $63 billion worth of such loans sound tiny relative to the mortgage books of the big four (CBA’s alone is worth around $500 billion), it’s still potentially big enough to trigger an earnings collapse in bank profits.

    Another overlooked risk factor

    Meanwhile, there’s a second possible structural change looming. As highlighted in my article this week, mega mall operators could also be forced to change their business model as the coronavirus shut-in accelerated the shift to online shopping.

    I suspect these shopping destinations have reached their peak in terms of their strategic value and we could also see write-downs in these assets.

    Structural change takes years to manifest. The fact that bankers are already starting to worry about some of these trends is a warning to investors not to take their eye off these emerging challenges.

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off it’s high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    Motley Fool contributor Brendon Lau owns shares of Australia & New Zealand Banking Group Limited, Commonwealth Bank of Australia, National Australia Bank Limited, and Westpac Banking. Connect with me on Twitter @brenlau.

    The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post The hidden threat to big banks that may be worse than a housing collapse appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3bQZbmb

  • Rates on home loans are dipping below 3% thanks to the Fed and Powell

    Rates on home loans are dipping below 3% thanks to the Fed and PowellThe central bank's words and actions have sent mortgage rates through the floor.

    from Yahoo Finance https://ift.tt/2LNqEKK

  • Can Moderna Win the COVID-19 Vaccine Race?

    Can Moderna Win the COVID-19 Vaccine Race?And just like that, the global race to advance a COVID-19 vaccine got turned up a notch. On Monday, mRNA specialist Moderna (MRNA) announced positive data regarding its COVID-19 vaccine candidate, mRNA-1273.5-star Oppenheimer’s Hartaj Singh applauds Moderna’s “unprecedented pace of development” and highlights the vaccine’s potential to accelerate the mRNA platform’s progress.  In the first stage of the Phase 1 study across three different dose groups (25, 100, 250 µg), following the analysis of eight patients’ data, all developed neutralizing antibodies which stopped the virus from replicating. Additionally, the study showed the vaccine was safe, and that the higher the vaccine dose, the more antibodies were produced, matching or exceeding the level of antibodies in people who have recovered from COVID-19. These are the first results to come from human trials of a vaccine against COVID-19. The company plans to initiate mRNA-1273's Phase 2 shortly and Phase 3 in July. Singh commented, “Based on the strong immunogenicity data and tolerable safety profiles mRNA-1273 has demonstrated, we increase the probability of success of mRNA-1273 to 50%… We continue to see a fast-rising opportunity for MRNA as mRNA-1273 leaps closer toward potential commercialization. As the opportunities following mRNA-1273 assume a weightier share of our valuation going forward, we remind investors of the potential of the mRNA platform, and its potential to bring forward a new class of medicines.” Bearing this in mind, Singh reiterated an Outperform rating on Moderna shares, while boosting the price target from $62 to $108. Should the analyst’s thesis play out in the coming months, 47% upside could be in the cards. (To watch Singh’s track record, click here) Most of the Street agrees with the Oppenheimer analyst. The analyst consensus rates MRNA a Strong Buy based on 9 Buys and 2 Holds. The $91.78 average price target indicates possible upside of 25% over the coming months. (See Moderna stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/3bMpTfz